Open AccessEfficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma
Author(s) -
Georgina V. Long,
Axel Hauschild,
Mario Santinami,
Victoria Atkinson,
Mario Mandalà,
Vanna Chiarion-Sileni,
James Larkin,
Marta Nyakas,
Caroline Dutriaux,
Andrew Haydon,
Caroline Robert,
Laurent Mortier,
Jacob Schachter,
Dirk Schadendorf,
Thierry Lesimple,
Ruth Plummer,
Ran Ji,
Pingkuan Zhang,
Bijoyesh Mookerjee,
Jeffery J. Legos,
Richard Kefford,
Reinhard Drummer,
John M. Kirkwood
Publication year - 2018
Publication title -
skin
Language(s) - English
Resource type - Journals
ISSN - 2574-1624
DOI - 10.25251/skin.2.supp.43
Subject(s) - dabrafenib , trametinib , placebo , medicine , adjuvant , stage (stratigraphy) , melanoma , oncology , dermatology , cancer research , pathology , vemurafenib , mapk/erk pathway , chemistry , metastatic melanoma , biology , phosphorylation , paleontology , biochemistry , alternative medicine
not available. Disclosures: Study sponsored by Novartis. Copyright 2018 SKIN